Incurs Net Loss Of Rs 62 Crore

Glenmark Pharmaceuticals Ltd. reported a net loss in the second quarter of fiscal 2024.

The Mumbai-based bulk and generic drugmaker incurred a net loss of Rs 61.6 crore in the quarter ended September. That compares with the profit of Rs 260 crore consensus estimate of analysts tracked by Bloomberg.

Leave a Comment